Imhotex
Develops a drug candidate for Crohn’s disease through a virtual biopharmaceutical model
Highlights
- New on EvolcAdded 2026-11-13
About Imhotex
Imhotex is a virtual biopharmaceutical company developing a product candidate to treat Crohn’s disease. It advances the candidate through specialist service providers.
The company was founded in 2020 and is based in Cambridge, UK. Its focus is bringing a drug candidate into clinical development.
Product: A drug candidate in development for Crohn’s disease.
Jobs at Imhotex
More biotech & pharma companies
immunesystems.co.uk
UK supplier of antibodies, ELISA kits, labeling kits and lab reagents for life sciences researchers and producersNew on EvolcImmunocore
Develops bispecific T cell receptor immunotherapies for cancer, infectious and autoimmune diseasesImmunokey
Develops CAR T-cell therapies for solid cancers, starting with ovarian cancerYoung companyNew on Evolcimmunologicaltoolbox.co.uk
Online antibody repository for veterinary immunology researchers, with community ratings and reagent requestsImmunoserv
Immunology laboratory services and T-cell testing products for industry, academia and consumers in the UKNew on EvolcImmutrin
Develops antibody therapies to remove amyloid deposits for people with amyloidosis, including ATTR cardiomyopathyNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content management
- WordPressHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Forms
- Google reCAPTCHAHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
- WPFormsHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Frontend frameworks
- jQueryHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.